News >

Expert Discusses Pembrolizumab Plus Rituximab in Follicular Lymphoma

Danielle Bucco
Published: Monday, Jul 24, 2017

Loretta J. Nastoupil, MD

Loretta J. Nastoupil, MD
Pembrolizumab (Keytruda) in combination with rituximab (Rituxan) has shown high response rates in patients with relapsed follicular lymphoma, according to findings from an open label phase II trial.

Nastoupil, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discussed the positive interim analysis and shared her thoughts on areas of future investigation for patients with relapsed follicular lymphoma.

OncLive: Can you provide an overview of the study?

Nastoupil: What we are presenting here at the 2017 Lugano International Conference for Malignant Lymphoma was a single institution phase II study investigating rituximab in combination with pembrolizumab in patients with relapsed follicular lymphoma. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication